Funded Biotechnology Startups in Boulder
The 20 most recent funding rounds for Boulder, Colorado biotechnology companies span from September 2021 through August 2025, with disclosed amounts rangin…
The 20 most recent funding rounds for Boulder, Colorado biotechnology companies span from September 2021 through August 2025, with disclosed amounts ranging from $250K (TissueForm, May 2023) to $375M (SomaLogic's post-IPO equity, September 2021). The mix of stages is notable: three companies — SomaLogic, Edgewise Therapeutics, and Viridian Therapeutics — have raised post-IPO rounds, while seed-stage deals like BioLoomics ($9M, September 2023) and Think Bioscience ($6M, May 2024) reflect continued early-stage formation in the market.
Enliven Therapeutics' $230M Series Unknown in June 2025 is the largest disclosed amount among recent activity. Enveda Biosciences raised twice within nine months, closing a $55M Series B in June 2024 and a $20M Series C in February 2025. Round type transparency is uneven across the dataset: a significant share of rounds are classified as "Series Unknown," covering deals as small as Encision's $500K (August 2025) and as large as OnKure Therapeutics' $65M (October 2024).
Most recent rounds
20 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Boulder biotech companies in this dataset?
The three largest are SomaLogic's $375M post-IPO equity round (September 2021), Enliven Therapeutics' $230M Series Unknown (June 2025), and Edgewise Therapeutics' $138M post-IPO equity (September 2022). Viridian Therapeutics' $75M post-IPO debt (April 2022) and OnKure Therapeutics' $65M Series Unknown (October 2024) round out the top five disclosed amounts.
How many Boulder biotech companies in this data have raised post-IPO capital?
Three companies have post-IPO rounds in the dataset: SomaLogic ($375M post-IPO equity, Sept 2021), Edgewise Therapeutics ($138M post-IPO equity, Sept 2022), and Viridian Therapeutics ($75M post-IPO debt, Apr 2022). Their presence alongside seed-stage companies like Think Bioscience and BioLoomics illustrates the range of maturities active in Boulder biotech.
Are there any companies that raised multiple rounds in this dataset?
Enveda Biosciences appears twice: a $55M Series B in June 2024 followed by a $20M Series C in February 2025, both within a nine-month window.
What does early-stage funding activity look like in this segment?
Seed rounds include BioLoomics ($9M, September 2023) and Think Bioscience ($6M, May 2024). Series A activity covers Watchmaker Genomics ($40M, June 2022), Bond Pet Foods ($18M, September 2022), and Proov (undisclosed, November 2021).
How active has Boulder biotech funding been in 2024 and 2025?
Six of the 20 rounds closed between January 2024 and August 2025, including Enliven Therapeutics' $230M, OnKure Therapeutics' $65M, Enveda Biosciences' $55M Series B, Think Bioscience's $6M seed, VitriVax's $4M, and Enveda Biosciences' $20M Series C.
How common is undisclosed or unknown round classification in this segment?
Several rounds carry no disclosed amount — Earable (June 2023), LightDeck Diagnostics (June 2022), and Proov (November 2021) — while many others are typed as 'Series Unknown,' a classification that spans a wide range from TissueForm's $250K (May 2023) to Enliven Therapeutics' $230M (June 2025).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.